| Title |
Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab
|
|---|---|
| Published in |
Pediatric Health, Medicine and Therapeutics, April 2015
|
| DOI | 10.2147/phmt.s40948 |
| Pubmed ID | |
| Authors |
Bella Zeisler, Jeffrey S Hyams |
| Abstract |
Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn's disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory approval was secured many years following approval for adults. The long delay between adult and pediatric approval has led to many years of off-label use of adalimumab, although it is anticipated that the use of adalimumab may further increase with official regulatory approval. To date, pediatric literature on the use of adalimumab for treatment of CD is limited, and pediatric practitioners have mostly extrapolated from research and experience provided by the adult literature. The aim of this paper is to review the literature regarding adalimumab for the treatment of pediatric CD, and includes a review of landmark adult studies as well as the pivotal pediatric study that facilitated regulatory approval. We also discuss the role of anti-tumor necrosis factor alpha agents including adalimumab in the current treatment paradigm for pediatric CD. |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 29% |
| Researcher | 2 | 14% |
| Student > Ph. D. Student | 1 | 7% |
| Other | 1 | 7% |
| Professor | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 4 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 43% |
| Business, Management and Accounting | 1 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Immunology and Microbiology | 1 | 7% |
| Computer Science | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 4 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2015.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Pediatric Health, Medicine and Therapeutics
#153
of 172 outputs
Outputs of similar age
#240,603
of 279,164 outputs
Outputs of similar age from Pediatric Health, Medicine and Therapeutics
#3
of 3 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 172 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,164 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.